Decentralized clinical trials ppt

1

• DECENTRALISATION
• THE FUTURE OF CLINICAL TRIALS

2
WHAT MAKES DECENTRALISATION THE FUTURE OF
CLINICAL TRIALS?
CROs to take the first step toward the future of
clinical trials With the emergence of COVID- 19
, Decentralisation of Clinical Trials became
necessary to comply with social distancing
requirements while carrying out clinical
research. Over the past few years, the clinical
trial landscape has shifted i ts focus to
patient- centric practices to promote patient
engagement. But now as the pandemic is long
gone, i t is t ime to reflect on how DCT studies
are genuinely addressing long- standing issues
in research and development for sponsors, study
teams, and of course, the patients!
ClinionAI
3
WHAT IS A

• DECENTRALISED CLINICAL TRIAL?
• Decentralised clinical trials involve a
  combination of innovative technologies with a
  patient- centric study design to communicate
  with study participants and
• collect data for conducting clinical studies
  using a hybrid approach

The primary goal of DCT is to provide a hybrid,
flexible system that can promote high patient
engagemen
ClinionAI
4
Traditional trials vs Decentralised trials
Site-centred advertising targeting local
participants
Digital advertising, allowing CROs to reach a
diverse patient population. E-consent (digital
consent signature) form patients located far
away from the site
In-person consent, via physical
signature In-person physical tests In-person
recruitment On-site treatment and check up where
patients have to visit the site Low due to
scheduled in-person patient visits
Tele-consultation and home visits by medical
personnel and nursing staff Virtual
recruitment Home healthcare and
teleconsultation. Remote monitoring by devices
and self- care platforms
Delayed Requires final in- person visits
5
WHY DECENTRALISED CLINICAL TRIALS ARE THE WAY
OF THE FUTURE?
With the growing need for accelerated drug
development, traditional site- centric clinical
trial models have evolved to handle consumer
requirements during unforeseen events. According
to recent data published by the Globaldata
Pharma Intelligence Center, decentralised or
remote clinical trials have successfully brought
research closer to the patients, with an overall
increase of 1.3 of all trials in 2011 to 2.5 in
2020.
Allows for a greater geographical reach, which
is important for enrolling a diverse group of
participants.
Eliminates the need for travel, which can be a
barrier to participation.
6
CONTACT CORPORATE
To get started with Clinion integrated DCT
platform, reach out to our experts!
EMAIL ADDRESS sales_at_clinion.com
PHONE NUMBER 91 733 738 2327
WEBSITE https//www.clinion.com/
7
THANK YOU!!
REVOLUTIONISE YOUR CLINICAL TRIAL EXPERIENCE WITH
AI- ENABLED AUTOMATION